Related references
Note: Only part of the references are listed.Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
Michael Horowitz et al.
ADVANCES IN THERAPY (2013)
Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats
Roger Reidelberger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Alterations in energy balance following exenatide administration
David P. Bradley et al.
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM-PHYSIOLOGIE APPLIQUEE NUTRITION ET METABOLISME (2012)
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Vanita R. Aroda et al.
CLINICAL THERAPEUTICS (2012)
Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity The Case for Personalized Combinatorial Therapies
Matthias H. Tschoep et al.
DIABETES (2012)
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
A. J. Scheen
DIABETES & METABOLISM (2012)
Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Jody Dushay et al.
DIABETES CARE (2012)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia
S. Herzberg-Schaefer et al.
DIABETES OBESITY & METABOLISM (2012)
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus
M. Davies et al.
DIABETES OBESITY & METABOLISM (2012)
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
F. K. Knop et al.
DIABETES OBESITY & METABOLISM (2012)
Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight
J. Jelsing et al.
DIABETES OBESITY & METABOLISM (2012)
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
G. Grunberger et al.
DIABETIC MEDICINE (2012)
Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass
C. Dirksen et al.
DIABETOLOGIA (2012)
Anti-obesity drugs: a review about their effects and their safety
Giuseppe Derosa et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes
Galina Smushkin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women
Pernille F. Svendsen et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Jens J. Holst et al.
DIABETES CARE (2011)
An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
S. Madsbad et al.
DIABETES OBESITY & METABOLISM (2011)
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M. A. Nauck et al.
DIABETOLOGIA (2011)
Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Scott E. Kanoski et al.
ENDOCRINOLOGY (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice
Michael M. Scott et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
GLP-1 and energy balance: an integrated model of short-term and long-term control
Jason G. Barrera et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Caroline M. Apovian et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor
Martha C. Washington et al.
BRAIN RESEARCH (2010)
PYY3-36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
Benjamin C. T. Field et al.
DIABETES (2010)
Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
Arterial Destiffening With Weight Loss in Overweight and Obese Middle-Aged and Older Adults
A. Laura Dengo et al.
HYPERTENSION (2010)
Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
Adam M. Deane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Hepatic-Portal Vein Infusions of Glucagon-Like Peptide-1 Reduce Meal Size and Increase c-Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats
I. Baumgartner et al.
JOURNAL OF NEUROENDOCRINOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
T. Edholm et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2010)
Obesity and leptin resistance: distinguishing cause from effect
Martin G. Myers et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes The Sleep AHEAD Study
Gary D. Foster et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
P. V. Hojberg et al.
DIABETOLOGIA (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Gut Peptides: Targets for Antiobesity Drug Development?
Timothy H. Moran et al.
ENDOCRINOLOGY (2009)
Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
Elisabeth B. Ruettimann et al.
ENDOCRINOLOGY (2009)
Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Diana L. Williams et al.
ENDOCRINOLOGY (2009)
Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions
Gregory M. Holmes et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Association of Body Mass and Brain Activation during Gastric Distention: Implications for Obesity
Dardo Tomasi et al.
PLOS ONE (2009)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
How strong is the association between abdominal obesity and the incidence of type 2 diabetes?
N. Freemantle et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Molecular physiology of weight regulation in mice and humans
R. L. Leibel
INTERNATIONAL JOURNAL OF OBESITY (2008)
Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain
Steffen Runge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Bariatric Surgery: Risks and Rewards
Walter J. Pories
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study
Guangwei Li et al.
LANCET (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
The obesity epidemic: Pharmacological challenges
Stephen R. Bloom et al.
MOLECULAR INTERVENTIONS (2008)
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
Elza Muscelli et al.
DIABETES (2008)
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
Kirsten Vollmer et al.
DIABETES (2008)
Influence of BMI and gender on postprandial hormone responses
Joan F. Carroll et al.
OBESITY (2007)
Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat
Shalea Piteau et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Effects of lifestyle intervention on health care costs: Improving Control With Activity and Nutrition (ICAN)
Anne M. Wolf et al.
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION (2007)
Reduced incretin effect in type 2 diabetes - Cause or consequence of the diabetic state?
Filip K. Knop et al.
DIABETES (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Medicare's search for effective obesity treatments - Diets are not the answer
Traci Mann et al.
AMERICAN PSYCHOLOGIST (2007)
Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation
Diana L. Williams et al.
DIABETES (2006)
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Jakob Ryskjaer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs
Carl Frederik Nagell et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus
Erik Hansen et al.
SURGERY (2006)
Signals that influence food intake and body weight
SC Woods
PHYSIOLOGY & BEHAVIOR (2005)
Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes
PE Cryer
DIABETES (2005)
Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects
TCM Adam et al.
BRITISH JOURNAL OF NUTRITION (2005)
The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
CR Abbott et al.
BRAIN RESEARCH (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem
E Alvarez et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Physical activity, body risk of type 2 diabetes in patients with normal or impaired glucose regulation
G Hu et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
LL Baggio et al.
DIABETES (2004)
Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes
MA Nauck et al.
REGULATORY PEPTIDES (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells
Y Anini et al.
ENDOCRINOLOGY (2003)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
International union of pharmacology.: XXXV.: The glucagon receptor family
KE Mayo et al.
PHARMACOLOGICAL REVIEWS (2003)
The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects
LL Kjems et al.
DIABETES (2003)
Role of leptin in the regulation of glucagon-like peptide-1 secretion
Y Anini et al.
DIABETES (2003)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Muscarinic receptors control postprandial release of glucagon-like peptide-1:: In vivo and in vitro studies in rats
Y Anini et al.
ENDOCRINOLOGY (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
WC Knowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans
J Schirra et al.
GUT (2002)
A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans
C Verdich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction
C Verdich et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
MB Toft-Nielsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
J Larsen et al.
DIABETES CARE (2001)
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
A Flint et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J Tuomilehto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients
T Vilsboll et al.
DIABETES (2001)
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
FR de Fonseca et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
A Flint et al.
INTERNATIONAL JOURNAL OF OBESITY (2000)
Share Paper
